KEEP is designed to meet the unique challenges faced by breast cancer patients, helping manage their daily dosing regimens seamlessly integrating into patients’ lives, improving adherence and reducing treatment burdens. In tandem, KEEP supports new product launches for pharma, unlocking deep insights into the patient experience.
passively capture dosing events
real time insights for manufacturers and health system partners
Key Challenge:
Blind to the patient journey, post Rx dispense
KEEP’s Solution:
KEEP provides a lens to the medication experience in the home, identifying leading indicators to therapy discontinuation, and catalyst to salvage strategies
Key Challenge:
Ensuring short and long term success of new patient starts
KEEP’s Solution:
KEEP provide passive medication tracking, personalized reminders, and caregiver enablement, supporting the development of critical initiation and long-term medication rituals
Key Challenge:
Establish early adoption and trust with prescribers
KEEP’s Solution:
Create an engagement point with KOL by building an RWE moat through monitoring, measuring and publishing real-world experience of Cami post -launch
While real-world data captures how patients take their medication, KEEP goes beyond that with Real World Experience (RWE-X). RWE-X captures the true, human experience of living with breast cancer, giving pharma companies insights into how patients navigate their day-to-day lives with their treatment. This deeper understanding allows healthcare providers to offer more personalized and timely support, ultimately improving outcomes and patient satisfaction.
Pilot Phase
In the initial pilot phase, KEEP will be deployed to a select group of patients on Camizestrant to demonstrate its impact on adherence and patient engagement.
Evaluation & Scaling
Following the pilot, we’ll assess the results and work with your team to fine-tune KEEP’s features to ensure maximum benefit for all patients on Camizestrant.
Full-Scale Rollout
Once the pilot is complete, KEEP will be rolled out across all Camizestrant patients, helping you deliver improved adherence and engagement at scale.
